Redmile Group, LLC Xencor Inc Transaction History

Redmile Group, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$32.75 - $41.43 $28.8 Million - $36.4 Million	-879,627 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$33.73 - $46.27 $24.7 Million - $33.9 Million	-733,171 Reduced 45.46%	879,627 $29.7 Million
Q2 2019 Aug 14, 2019	SELL	$29.6 - $40.93 $42.1 Million - $58.3 Million	-1,423,805 Reduced 46.89%	1,612,798 $66 Million
Q1 2019 May 15, 2019	SELL	$27.85 - $38.09 $1.34 Million - $1.83 Million	-48,100 Reduced 1.56%	3,036,603 $94.3 Million
Q4 2018 Feb 14, 2019	BUY	$32.39 - $42.05 $1.77 Million - $2.29 Million	54,560 Added 1.8%	3,084,703 $112 Million
Q3 2018 Nov 14, 2018	SELL	$35.69 - $47.65 $4.17 Million - $5.57 Million	-116,900 Reduced 3.71%	3,030,143 $118 Million
Q2 2018 Aug 14, 2018	SELL	$28.41 - $42.41 $1.63 Million - $2.43 Million	-57,300 Reduced 1.79%	3,147,043 $116 Million
Q1 2018 May 15, 2018	BUY	$21.18 - $33.78 $39.3 Million - $62.6 Million	1,853,449 Added 137.2%	3,204,343 $0
Q4 2017 Feb 14, 2018	BUY	$19.29 - $24.83 $2.91 Million - $3.74 Million	150,600 Added 12.55%	1,350,894 $29.6 Million
Q3 2017 Nov 14, 2017	BUY	$19.61 - $23.35 $23.5 Million - $28 Million	1,200,294	1,200,294 $27.5 Million

198

73.7M

1.7K

4.2K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $670M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.